Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / KIT



This biomarker is also known as:
  • v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog,
  • CD117,
  • mast/stem cell growth factor receptor Kit,
  • Piebald trait protein,
  • soluble KIT variant 1,
  • p145 c-kit,
  • C-Kit,
  • SCFR,
  • PBT,
  • SCF-sR,
  • tyrosine-protein kinase Kit,
  • v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein,
  • proto-oncogene c-Kit,
  • Piebald trait,
  • CD117 antigen,
  • proto-oncogene tyrosine-protein kinase Kit,

View in BioMuta


SCF-sR, also known as KIT, is the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. Human KIT is a tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KIT is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


KIT is known to be expressed in poorly differentiated breast cancer. (PMID:17867595). KIT is also thought to be a possible prognostic marker and possible molecular target for therapy in patients with BLBC. (PMID: 23319435)

Performance Comment

KIT was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.



Phase: Two
QA State: Curated


KIT has not been identified previously in serum as a lung cancer biomarker and represents a novel finding in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

SCF-sR, also known as KIT, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.